Physician profile
Christopher A Bell
NPI 1467450908
$11,198.57
in general payments reported to CMS, 2019-2025
50 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $1,732 · 2021: $1,885 · 2022: $2,113 · 2023: $1,870 · 2024: $1,088 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,954 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,953.88 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,106.76 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,620.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $1,482.21 | 2019-2025 | Trintellix |
| Pfizer INC. | $782.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $748.92 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $604.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.59 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $351.13 | 2019-2022 | |
| Lilly USA, LLC | $341.10 | 2020-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $276.91 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.42 | 2019-2022 | |
| Allergan, INC. | $178.59 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $173.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $156.99 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $152.35 | 2020-2023 | Livalo, Seglentis |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.